BioHeart, a biotechnology company focused on the discovery, development, and commercialization of therapies using cells derived from a patients body for the treatment of heart damage, filed for an IPO on Tuesday. BMO Capital Markets will be the sole book-running manager on the deal. Terms and timing are yet to be announced.
